{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-115765","form_type":"8-K","ticker":"HURA","cik":"0001498382","company_name":"TuHURA Biosciences, Inc./NV","filed_at":"2024-10-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.597540+00:00","generated_at":"2026-05-30T12:20:25.693415+00:00","sec_items":["2.01","1.01","9.01","5.02","2.02","3.03","5.01","5.03","5.06","8.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Kintara completes reverse merger with TuHURA; renamed TuHURA Biosciences, trades as HURA","bullets":["Merger closed Oct 18, 2024; Kintara securityholders own ~2.85% of combined entity (or 5.45% if CVR milestone met).","TuHURA securityholders own ~97.15% (or 94.55% after CVR shares).","1-for-35 reverse stock split pre-merger; common stock now trades under HURA on Nasdaq.","CVRs issued to former Kintara holders; up to ~1.54M shares payable if REM-001 CMBC study milestone met by Dec 31, 2025.","Combined company focuses on TuHURA's personalized cancer vaccine IFx-2.0; Phase 3 trial in MCC planned for Q1 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-115765","json":"https://secwatch.observer/filing/0000950170-24-115765.json","markdown":"https://secwatch.observer/filing/0000950170-24-115765.md","text":"https://secwatch.observer/filing/0000950170-24-115765.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1498382/000095017024115765/0000950170-24-115765-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1498382/000095017024115765/hura-20241018.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T12:20:25.693415+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}